title: Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
abstract: OBJECTIVE
  This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS).
  
  
  METHODS
  Subjects (7-17 years old) with ADHD (Diagnostic and Statistical Manual of Mental Disorders, DSM-IV) and TS were randomly assigned to double-blind treatment with placebo (n = 56) or atomoxetine (0.5-1.5 mg/kg/day, n = 61) for approximately 18 weeks.
  
  
  RESULTS
  Atomoxetine subjects showed significantly greater improvement on ADHD symptom measures. Treatment was also associated with significantly greater reduction of tic severity on two of three measures. Significant increases were seen in mean pulse rate and rates of treatment-emergent nausea, decreased appetite, and decreased body weight. No other clinically relevant treatment differences were observed in any other vital sign, adverse event, laboratory parameter, or electrocardiographic measure.
  
  
  CONCLUSIONS
  Atomoxetine is efficacious for treatment of ADHD and its use appears well tolerated in ADHD patients with comorbid TS.
authors.affiliation: Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114-2696, USA. tspencer@partners.org
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Spencer
authors.forename: F Randy
authors.initials: FR
authors.lastname: Sallee
authors.forename: Donald L
authors.initials: DL
authors.lastname: Gilbert
authors.forename: David W
authors.initials: DW
authors.lastname: Dunn
authors.forename: James T
authors.initials: JT
authors.lastname: McCracken
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Coffey
authors.forename: Cathy L
authors.initials: CL
authors.lastname: Budman
authors.forename: Randall K
authors.initials: RK
authors.lastname: Ricardi
authors.forename: Henrietta L
authors.initials: HL
authors.lastname: Leonard
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Allen
authors.forename: Denai R
authors.initials: DR
authors.lastname: Milton
authors.forename: Peter D
authors.initials: PD
authors.lastname: Feldman
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Kelsey
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Geller
authors.forename: Steven L
authors.initials: SL
authors.lastname: Linder
authors.forename: Donald W
authors.initials: DW
authors.lastname: Lewis
authors.forename: Paul K
authors.initials: PK
authors.lastname: Winner
authors.forename: Roger M
authors.initials: RM
authors.lastname: Kurlan
authors.forename: Mark
authors.initials: M
authors.lastname: Mintz
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology*; D002648:Child; D015897:Comorbidity; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011437:Propylamines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D005879:Tourette Syndrome / Q000175:diagnosis / Q000453:epidemiology*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride